JP5993112B2 - Antidepressant - Google Patents

Antidepressant Download PDF

Info

Publication number
JP5993112B2
JP5993112B2 JP2011018027A JP2011018027A JP5993112B2 JP 5993112 B2 JP5993112 B2 JP 5993112B2 JP 2011018027 A JP2011018027 A JP 2011018027A JP 2011018027 A JP2011018027 A JP 2011018027A JP 5993112 B2 JP5993112 B2 JP 5993112B2
Authority
JP
Japan
Prior art keywords
culture
extract
medium
water
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011018027A
Other languages
Japanese (ja)
Other versions
JP2012158536A (en
Inventor
康英 日比野
康英 日比野
飯塚 博
博 飯塚
真理 岡崎
真理 岡崎
広和 松崎
広和 松崎
Original Assignee
野田食菌工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 野田食菌工業株式会社 filed Critical 野田食菌工業株式会社
Priority to JP2011018027A priority Critical patent/JP5993112B2/en
Publication of JP2012158536A publication Critical patent/JP2012158536A/en
Application granted granted Critical
Publication of JP5993112B2 publication Critical patent/JP5993112B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Description

本発明は、抑うつ感、不安感、恐怖感、意欲低下、いらいら感等の精神的なうつ症状の改善又は予防のために用いられる抗うつ剤に関する。   The present invention relates to an antidepressant used for the improvement or prevention of mental depressive symptoms such as depression, anxiety, fear, reduced motivation, and irritation.

現代のストレス社会において、うつ病の患者数は増加傾向にあり、その予防および治療対策が望まれている。これまでの抗うつ剤はモノアミンの再取り込み阻害がその主たる作用機序であった。しかしながら従来の抗うつ剤は約3割の患者において効果が認められないという報告なども存在し、新たな作用機序の抗うつ剤が求められている。また、副作用なく安全に服用できる抗うつ剤が望まれている。   In the modern stress society, the number of patients with depression is increasing, and prevention and treatment measures are desired. Until now, the main mechanism of action of antidepressants was inhibition of monoamine reuptake. However, there are reports that conventional antidepressants are not effective in about 30% of patients, and antidepressants with a new mechanism of action are required. In addition, an antidepressant that can be safely taken without side effects is desired.

一方、従来、食用キノコ類を、抗うつ剤の配合成分として利用することが知られている。例えば、特許文献1には、ホップエキスを主成分とする香辛料、甘草、当帰、セリの根およびきのこ類の群から選ばれたすくなくとも一つの食品素材の粉末またはエキスを含有し、うつに対する抗うつ作用を有することを特徴とする抗うつ病用食品の発明が開示され、きのこ類として、乾燥品であるシイタケ、生鮮品のシメジ等が挙げられている(特許文献1の特許請求の範囲、段落0012参照)。また、特許文献2には、マイタケを配合したことを特徴とする、軽度のうつ病もしくはうつ状態の精神症状の予防または改善剤の発明が開示されている(特許文献2の請求項4参照)。   On the other hand, it is conventionally known to use edible mushrooms as a component of an antidepressant. For example, Patent Document 1 contains a powder or extract of at least one food material selected from the group consisting of spices mainly composed of hop extract, licorice, toki, seri-root, and mushrooms, and is resistant to depression. The invention of an antidepressant food characterized by having a depressing action is disclosed, and mushrooms include dried shiitake mushrooms, fresh product shimeji, etc. (Claims of Patent Document 1, (See paragraph 0012). Patent Document 2 discloses an invention of a preventive or ameliorating agent for psychiatric symptoms of mild depression or depression, characterized by blending maitake (see claim 4 of Patent Document 2). .

特開2002−58450号公報JP 2002-58450 A 特開2005−325096号公報JP 2005-325096 A

しかしながら、キノコ類の子実体の粉末や水抽出物を有効成分とする抗うつ剤では、必ずしもその効果が十分とはいえなかった。   However, an antidepressant comprising a mushroom fruit body powder or water extract as an active ingredient has not always been sufficiently effective.

したがって、本発明は、キノコ類等の担子菌由来成分を有効成分とし、副作用なく安全に服用できる抗うつ剤であって、うつ症状を改善又は予防する効果の高いものを提供することにある。   Therefore, an object of the present invention is to provide an antidepressant that has a basidiomycete-derived component such as mushrooms as an active ingredient and can be safely taken without side effects, and has a high effect of improving or preventing depressive symptoms.

上記目的を達成するため、本発明は、植物繊維質原料を含む培地を用いて担子菌の菌糸体を培養し、その培養物から抽出して得た、糖質、蛋白質、及び水溶性リグニンを含む抽出物を有効成分として含有することを特徴とする抗うつ剤を提供するものである。   In order to achieve the above object, the present invention cultivates mycelia of basidiomycetes using a medium containing plant fiber raw materials, and extracts carbohydrates, proteins, and water-soluble lignin obtained by extraction from the culture. The present invention provides an antidepressant characterized by containing an extract containing it as an active ingredient.

本発明の抗うつ剤においては、前記抽出物は、前記培養物から、担子菌の自己消化を行って得られたものであることが好ましい。   In the antidepressant of the present invention, it is preferable that the extract is obtained by performing autolysis of basidiomycetes from the culture.

また、前記植物繊維質原料が、禾本科植物から調製されたものであることが好ましく、バガス、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅、熊笹、及び竹から選ばれた1種又は2種以上から調製されたものであることがより好ましい。   In addition, the plant fiber raw material is preferably prepared from a plant family plant, one selected from bagasse, corn stover, wheat bran, rice bran, rice bran, rice bran, bear cocoon, and bamboo or More preferably, it is prepared from two or more.

更に、前記担子菌が、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、及びアガリクスから選ばれたものであることが好ましい。   Furthermore, it is preferable that the basidiomycete is selected from mannenpox, bukkyou, kofukisarokoshikake, kawara mushroom, shiitake mushroom, hira mushroom, mai mushroom, enoki mushroom, shimeji mushroom, yamabushi mushroom, and agaricus.

植物繊維質原料を含む培地を用いて担子菌の菌糸体を培養すると、培地中に含まれるセルロース、ヘミセルロース、リグニンなどが、培養期間中に担子菌の菌糸体が生産するセルラーゼ、フェノールオキシダーゼ、ラッカーゼ、パーオキシダーゼ、プロテアーゼなどの酵素により、消化、分解、及び縮合を起こしてペントース主体のプロテオグリカンを生成する。また、水溶性化した変性水溶性リグニンが生成する。本発明によれば、このように培養培地からの成分を複合的に含む抽出物を有効成分とすることにより、抑うつ感、不安感、恐怖感、意欲低下、いらいら感等の精神的なうつ症状を改善又は予防する効果が期待できる優れた抗うつ剤を提供することができる。また、その有効成分は天然物から得られた抽出物であり、日常的に、副作用なく安全に服用することができる。   When a mycelium of basidiomycetes is cultured using a medium containing plant fiber raw materials, cellulose, hemicellulose, lignin, etc. contained in the medium are cellulase, phenol oxidase, and laccase produced by mycelia of basidiomycetes during the culture period. Pentose-based proteoglycans are produced by digestion, degradation, and condensation with enzymes such as peroxidase and protease. Moreover, the water-soluble modified water-soluble lignin is generated. According to the present invention, mental extracts such as depression, anxiety, fear, reduced motivation, and irritability are obtained by using an extract containing the components from the culture medium in this way as an active ingredient. It is possible to provide an excellent antidepressant that can be expected to have an effect of improving or preventing the above. Moreover, the active ingredient is an extract obtained from a natural product, and can be safely taken on a daily basis without side effects.

ジアゼパム投与による高架式十字迷路試験の基礎検討の結果を示す図表である。It is a graph which shows the result of the basic examination of the elevated plus maze test by diazepam administration. MAK又はイミプラミンを投与したときの高架式十字迷路試験の結果を示す図表である。It is a graph which shows the result of an elevated plus maze test when MAK or imipramine is administered. イミプラミン投与による強制水泳試験の基礎検討の結果を示す図表である。It is a graph which shows the result of the basic examination of the forced swimming test by imipramine administration. MAK又はイミプラミンを投与したときの強制水泳試験の結果を示す図表である。It is a graph which shows the result of a forced swimming test when MAK or imipramine is administered.

本発明に用いられる担子菌としては、特に限定されず、例えば、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸などの薬用茸や、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、アガリクスなどの食用茸など各種のものが挙げられる。この中でも、特にマンネン茸、椎茸が好ましく採用される。   The basidiomycetes used in the present invention are not particularly limited, for example, medicinal mushrooms such as mannen mushrooms, bukkyou, kofukisarokoshikake, kawara mushrooms, shiitake mushrooms, Japanese cypress mushrooms, mai mushrooms, enoki mushrooms, shimeji mushrooms, yamabushi mushrooms, Various foods such as edible rice cakes such as Agaricus are listed. Among these, mannen mushrooms and shiitake mushrooms are particularly preferably employed.

本発明では、これらの担子菌の菌糸体を、植物繊維質原料を含む培地を用いて培養し、その培養物から有効成分を抽出する。この場合、培地としては、固体培地、液体培地の何れも使用できる。培地に用いる植物繊維質原料としては、リグニンを含有する植物から調製されたものが好ましく用いられる。リグニンを含有する植物としては、禾本科植物、例えばバガス(さとうきびの搾り粕)、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅などが好ましく用いられる。この他に、熊笹、竹なども使用できる。特に好ましくは、バガス、熊笹の茎葉、とうもろこしの茎から選ばれた少なくとも1種と、米糠とを含む培地が用いられる。また、培地には、必要に応じて他の栄養成分として、酵母エキス、乾燥酵母、クロレラ、スピルリナ、コーンミール、おからなどを添加混合してもよい。   In the present invention, mycelia of these basidiomycetes are cultured using a medium containing plant fiber raw material, and active ingredients are extracted from the culture. In this case, either a solid medium or a liquid medium can be used as the medium. As the plant fiber raw material used for the medium, those prepared from plants containing lignin are preferably used. As the lignin-containing plant, a plant family such as bagasse (squeezed sugar cane), corn stover, wheat bran, rice bran, rice straw, and straw are preferably used. In addition, bears, bamboo, etc. can be used. Particularly preferably, a culture medium containing at least one selected from bagasse, bear stems and corn stalks and rice bran is used. In addition, yeast extract, dry yeast, chlorella, spirulina, corn meal, okara, and the like may be added and mixed with the medium as other nutritional components as necessary.

担子菌の菌糸体の培養は、上記のような植物繊維質原料を含む培地に、前記担子菌の菌糸を接種して行う。固体培地の場合は、水分が60〜80%となるように調製し、常法に従い高圧蒸気滅菌した後、菌糸を接種し、例えば温度が18〜25℃に空調された培養室で3〜6か月培養する。こうして菌糸体が蔓延した培地は、温度処理室に移して変温処理を行うことが好ましい。変温処理は、例えば最初に30〜34℃で24〜48時間加温し、次に低温室に移して3〜5日間処理する。その後培養室に移すと子実体の発生が始まるが、この時点で培養を終了し、培養物を破砕機で破砕する。   The mycelium of basidiomycetes is cultured by inoculating the mycelium of basidiomycetes in a medium containing the above-mentioned plant fiber raw material. In the case of a solid medium, the water content is adjusted to 60 to 80%, sterilized by autoclaving according to a conventional method, inoculated with mycelia, and, for example, 3 to 6 in a culture room conditioned at a temperature of 18 to 25 ° C. Incubate for months. The medium in which the mycelium has spread is preferably transferred to a temperature treatment chamber and subjected to a temperature change treatment. In the temperature change treatment, for example, the mixture is first heated at 30 to 34 ° C. for 24 to 48 hours, and then transferred to a low temperature chamber and treated for 3 to 5 days. After that, when it is moved to a culture room, the generation of fruiting bodies starts. At this point, the culture is terminated and the culture is crushed with a crusher.

一方、液体培地の場合は、上記のような植物原料を細かく破砕し、必要に応じて米糠等の他の栄養成分を加え、原料が5〜20質量%となるように培地を調製した後、通気攪拌培養もしくは振盪培養により、好ましくは20〜28℃の温度で1週間〜2か月間程度培養を行う。培養は培地のpHが3.5〜5に低下し、培地中に菌糸が蔓延した状態で終了する。   On the other hand, in the case of a liquid medium, after pulverizing the plant raw material as described above, adding other nutritional components such as rice bran as necessary, and preparing the medium so that the raw material is 5 to 20% by mass, The culture is preferably carried out by aeration and agitation culture or shaking culture at a temperature of 20 to 28 ° C. for about 1 week to 2 months. The culture is terminated when the pH of the medium is lowered to 3.5 to 5 and the mycelium is prevalent in the medium.

培養終了後培養物を抽出する。その好ましい方法としては、菌糸体に内在する酵素を利用して菌糸体を自己消化させると共に培養物を抽出するようにすることが好ましい。   After completion of the culture, the culture is extracted. As a preferable method, it is preferable to self-digest the mycelium and extract the culture using an enzyme present in the mycelium.

具体的には、固体培地の場合は培養が終了した培養物を破砕し、必要に応じて少量の水を加え、30〜60℃で3〜6時間処理し、菌糸体の酵素反応を進め、自己消化させる。次いで、この破砕物を50℃以上の温水又は熱水に浸潤させ、有効成分を抽出する。抽出は、例えば1.2kg/cmの蒸気圧下で120℃というような加圧高温下で行うこともできる。こうして得られた抽出懸濁液を、好ましくは濾過または遠心分離して濾液又は上清を採取することにより、培地の分解物、菌糸体の代謝産物及び菌糸体細胞の分解物などを含む抽出物を得ることができる。 Specifically, in the case of a solid medium, the culture after culturing is crushed, a small amount of water is added as necessary, and the mixture is treated at 30 to 60 ° C. for 3 to 6 hours to advance the mycelial enzyme reaction, Let yourself digest. Subsequently, this crushed material is infiltrated with warm water or hot water of 50 ° C. or higher, and an active ingredient is extracted. The extraction can also be carried out under a high pressure such as 120 ° C. under a vapor pressure of 1.2 kg / cm 2 , for example. The extract suspension thus obtained is preferably filtered or centrifuged, and the filtrate or supernatant is collected to obtain an extract containing a degradation product of the culture medium, a mycelium metabolite, a mycelium cell degradation product, and the like. Can be obtained.

一方、液体培養の場合は、培養物全体を30〜60℃で3〜6時間処理し、菌糸体を自己消化させ、液体の懸濁培養物を得る。次いで、必要に応じて少量の水を加え、50℃以上、場合によっては高圧条件下(例えば1.2kg/cmの蒸気圧下)に加熱し、抽出物を採取する。この抽出物を、必要に応じて濾過又は遠心分離して濾液又は上清を採取することにより、培地の分解物、菌糸体の代謝産物及び菌糸体細胞の分解物などを含む抽出物を得ることができる。 On the other hand, in the case of liquid culture, the whole culture is treated at 30 to 60 ° C. for 3 to 6 hours to self-digest the mycelium to obtain a liquid suspension culture. Then, if necessary, a small amount of water is added, and the mixture is heated to 50 ° C. or higher, possibly under high pressure (for example, under a vapor pressure of 1.2 kg / cm 2 ), and the extract is collected. By filtering or centrifuging the extract as necessary, and collecting the filtrate or supernatant, an extract containing a degradation product of a medium, a mycelium metabolite, a mycelium cell degradation product, or the like is obtained. Can do.

こうして得られた抽出物は、液状のものをそのまま又は濃縮して利用することもできるが、凍結乾燥や噴霧乾燥などの手段によって粉末化して利用することもできる。抽出物として液状のものをそのまま又は濃縮して利用する場合には、例えば液状又はゼリー状のドリンクタイプの製品とすることもできる。抽出物を粉末化して利用する場合には、常法によって、粉末、顆粒、錠剤、カプセル剤等として製品化することができる。 The extract thus obtained can be used as it is or after being concentrated, but can also be used by pulverizing it by means such as freeze drying or spray drying. When using those liquid as such or concentrated to as extract, Ru can also be, for example, a liquid or jelly drink type products. When utilizing the extract was triturated a conventional method by, powders, granules, tablets, Ru can be manufactured as capsules and the like.

本発明の有効成分である上記抽出物(植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分)は、糖質を主体とした物質であるが、次のような物理化学的性質を有していることが好ましい。   The above extract, which is an active ingredient of the present invention (a component extracted from a culture obtained by culturing mycelia of basidiomycetes in a medium containing plant fiber raw material) is a substance mainly composed of carbohydrates. However, it is preferable to have the following physicochemical properties.

(1) 分子量:100万以下
(2) 化学組成:
・糖質:30〜50質量%
・蛋白質:8〜20質量%
・水溶性リグニン:20〜40質量%
(1) Molecular weight: 1 million or less (2) Chemical composition:
・ Sugar: 30-50% by mass
・ Protein: 8-20% by mass
Water-soluble lignin: 20-40% by mass

なお、上記抽出物中の糖質、蛋白質、及び水溶性リグニンの組成の範囲を特定するためには、それぞれフェノール硫酸法、セミミクロケルダール法、アセチルブロマイド法で測定して求められる質量組成で特定することが好ましい。   In addition, in order to specify the range of the composition of the saccharide, protein, and water-soluble lignin in the above extract, it is specified by the mass composition obtained by measurement by the phenol sulfuric acid method, the semi-micro Kjeldahl method, and the acetyl bromide method, respectively. It is preferable.

マンネン茸を用いて得られた上記培養抽出物(粉末)について安全性を試験した結果は次の通りである。   The results of testing the safety of the above culture extract (powder) obtained using mannen koji are as follows.

(A) 急性毒性試験(最小致死量)
・ラット単回経口投与 雄:22,500mg/Kg 以上
雌:22,500mg/Kg 以上
・マウス単回経口投与 雄:2,000mg/Kg 以上
雌:2,000mg/Kg 以上
(B) ラット3か月反復経口投与試験(最大無作用量)
雄:3,610mg/Kg
雌:4,190mg/Kg
(A) Acute toxicity test (minimum lethal dose)
・ Rat single oral administration Male: 22,500mg / Kg or more
Female: 22,500 mg / Kg or more ・ Single mouse oral administration Male: 2,000 mg / Kg or more
Female: 2,000 mg / Kg or more (B) Rat 3-month repeated oral administration test (maximum no-effect level)
Male: 3,610 mg / Kg
Female: 4,190mg / Kg

本発明の抗うつ剤の有効投与量は、上記抽出物の固形分換算で、経口摂取において成人1日当たり1〜10gである。投与量がこれよりも少ないと、抗うつ作用の効果が十分に得られず、投与量がこれよりも多いと、軟便又は腹部膨満感が生じることがある。ただし、投与量が上記より多くても安全性には問題がない。   The effective dose of the antidepressant of the present invention is 1 to 10 g per day for an adult in terms of oral intake in terms of solid content of the extract. If the dose is smaller than this, the effect of the antidepressant action is not sufficiently obtained, and if the dose is larger than this, loose stool or abdominal bloating may occur. However, there is no problem in safety even if the dose is larger than the above.

以下実施例を挙げて本発明を具体的に説明するが、これらの実施例は本発明の範囲を限定するものではない。   EXAMPLES Hereinafter, the present invention will be specifically described with reference to examples, but these examples do not limit the scope of the present invention.

(1)培養培地抽出物の調製例
<調製例1>(バガスを用いたマンネン茸菌の固体培養)
バガス90質量部と、脱脂米糠10質量部とを配合し、水分70%となるように調整して固形培地を作り、常法通り高圧蒸気滅菌した。この固体培地にマンネン茸の菌糸を接種し、25℃に温度調節した培養室内で3か月培養し、培地中に菌糸体が蔓延した後、温度処理室に移して35℃で24時間加温し、次いで10℃の低温室で3日間処理した。その後、上記培養室で3日間培養し、培地を破砕機で親指程度の大きさに破砕した。破砕した培地を40℃で6時間処理し、自己消化を促進させた後、抽出タンクに詰め、60℃の温水を循環させながら16時間抽出した。得られた抽出液をカートリッジフィルターで濾過し、更にメンブランフィルターで濾過除菌後、濃縮し、凍結乾燥により褐色の粉末を得た。その成分を分析した結果は以下の通りであった。
(1) Preparation Example of Culture Medium Extract <Preparation Example 1> (Solid culture of N. gonorrhoeae using bagasse)
90 parts by mass of bagasse and 10 parts by mass of defatted rice bran were mixed, adjusted to a moisture content of 70%, a solid medium was prepared, and autoclaved as usual. This solid medium is inoculated with mycelium of mannen moth and cultured in a culture chamber adjusted to 25 ° C. for 3 months. After the mycelium spreads in the medium, it is transferred to a temperature treatment chamber and heated at 35 ° C. for 24 hours. Then, it was treated in a low temperature room at 10 ° C. for 3 days. Then, it culture | cultivated for 3 days in the said culture room, and crushed the culture medium in the magnitude | size about the thumb with the crusher. The crushed medium was treated at 40 ° C. for 6 hours to promote autolysis, then packed in an extraction tank, and extracted for 16 hours while circulating 60 ° C. warm water. The obtained extract was filtered through a cartridge filter, further sterilized by filtration through a membrane filter, concentrated, and freeze-dried to obtain a brown powder. The results of analyzing the components were as follows.

・糖質 :40質量%(フェノール硫酸法)
・蛋白質 :12質量%(セミミクロケルダール法)
・水溶性リグニン :30質量%(アセチルブロマイド法)
・無機質 :13質量%(直接灰化法)
・ Sugar: 40% by mass (phenol sulfate method)
・ Protein: 12% by mass (semi-micro Kjeldahl method)
・ Water-soluble lignin: 30% by mass (acetyl bromide method)
・ Inorganic: 13% by mass (direct ashing method)

(2)動物試験
上記調製例1の方法で得たマンネン茸の菌糸体培養培地抽出物(以下、「MAK」という。)について、ラット(Sprague Dawley,、三協ラボサービス)を利用した動物試験により、その抗うつ効果を検討した。具体的には、MAKを1g/kgの投与量3mL/kgの容量で、ラットに1日1回経口ゾンデにて投与し、これを15日間続けて試験群とした(6匹)。また、抗うつ剤であるイミプラミンを、10mg/kgの投与量3mL/kgの容量で同様に投与し、これを陽性対照群とした(6匹)。更に、水のみを与えたラットを陰性対照群とした(6匹)。投与10日目のラットに高架式十字迷路試験を行い、投与14日目に強制水泳試験を行った。なお、試験当日は試験の1時間前に上記被検物質の投与を行った。
(2) Animal test The animal test using the rat (Sprague Dawley, Sankyo Lab Service) for the mycelium culture medium extract (hereinafter referred to as “MAK”) of mannen koji obtained by the method of Preparation Example 1 above. Thus, the antidepressant effect was examined. Specifically, MAK was administered to rats in an oral sonde once a day at a dose of 3 mL / kg at a dose of 1 g / kg, and this was continued for 15 days to form test groups (6 animals). Moreover, imipramine which is an antidepressant was similarly administered in a volume of 3 mL / kg at a dose of 10 mg / kg, and this was used as a positive control group (6 animals). Furthermore, rats fed with water alone served as a negative control group (6 animals). An elevated plus maze test was performed on the rats on the 10th day after administration, and a forced swimming test was performed on the 14th day after administration. On the test day, the test substance was administered 1 hour before the test.

以下、試験例1において高架式十字迷路試験の結果を示し、試験例2において強制水泳試験の結果を示す。   Hereinafter, the result of the elevated plus maze test is shown in Test Example 1, and the result of the forced swimming test is shown in Test Example 2.

<試験例1>(高架式十字迷路試験)
高架式十字迷路試験は、不安水準を評価する行動試験である。壁のない走行路(open arm;オープンアーム)と壁で囲まれている走行路(closed arm;クローズドアーム)が十字に交差する迷路を用いる。通常、被検動物は壁のない開かれた空間では不安や恐怖を感じるため、クローズドアームでの滞在時間が長くなる。抗不安薬の投与により、オープンアームでの滞在時間が増加する。本試験例では、迷路の上方に設置したビデオカメラによりラットの行動軌跡を取得し、ビデオトラッキングシステム(商品名「CompACT」、室町機械株式会社製)にて測定、解析し、行動指標として、10分間あたりのオープンアームとクローズドアームの両走行路への総進入回数(運動量)とオープンアーム滞在時間の割合(不安水準)を求めた。
<Test Example 1> (Elevated cross maze test)
The elevated plus maze test is a behavioral test that evaluates anxiety levels. A maze is used in which a road without a wall (open arm) and a road surrounded by a wall (closed arm) cross each other in a cross shape. Usually, the subject animal feels anxiety and fear in an open space without a wall, so that the staying time in the closed arm becomes long. Anti-anxiety medications increase open arm residence time. In this test example, a rat's behavior trajectory is acquired by a video camera installed above the maze, and measured and analyzed by a video tracking system (trade name “CompACT”, manufactured by Muromachi Kikai Co., Ltd.). We calculated the total number of times (momentum) and the percentage of open arm stay time (anxiety level) in both the open and closed arm tracks per minute.

図1には、基礎検討として、抗不安薬であるジアゼパムを0.5mg/kgの投与量で、ラットに試験の30分前に腹腔内投与したラット群について高架式十字迷路試験を行ったときの結果を示す。図1aに示すように、ジアゼパム投与により、オープンアームとクローズドアームの両走行路への総進入回数が、水のみを与えた対照に比べて増加しており、迷路内での運動量が増えていることが分かる。また、図1bに示すように、ジアゼパム投与により、オープンアーム滞在時間の割合が、水のみを与えた対照に比べて増加しており、不安水準が低減していることが分かる。   FIG. 1 shows, as a basic study, when an elevated plus maze test was conducted on a group of rats in which diazepam, an anxiolytic drug, was administered intraperitoneally 30 minutes before the test at a dose of 0.5 mg / kg. The results are shown. As shown in FIG. 1a, the diazepam administration increases the total number of times the open arm and the closed arm enter the runway compared to the control given water only, and the momentum in the maze is increased. I understand that. In addition, as shown in FIG. 1b, it can be seen that administration of diazepam increased the percentage of staying in the open arm compared to the control given water only, and the anxiety level was reduced.

図2には、MAK投与群とイミプラミン投与群の投与開始から10日目に行った高架式十字迷路試験の結果を示す。図2aに示すように、MAK投与により、オープンアームとクローズドアームの両走行路への総進入回数が、水のみを与えた対照に比べて増加し、また、図2bに示すように、オープンアーム滞在時間の割合が、水のみを与えた対照に比べて増加していた。この結果は、ジアゼパムを投与した場合と同様の傾向であった。したがって、MAK投与により、迷路内での運動量が増加し、また、不安水準が低減することが明らかとなった。一方、イミプラミン投与では、不安水準の低減は認められたが(図2b)、迷路内での運動量の増加は認められなかった(図2a)。   FIG. 2 shows the results of the elevated plus maze test conducted on the 10th day from the start of administration in the MAK administration group and the imipramine administration group. As shown in FIG. 2a, the MAK administration increases the total number of times the open arm and the closed arm enter the road compared to the control given water only, and as shown in FIG. The percentage of staying time was increased compared to controls given water only. This result was the same tendency as when diazepam was administered. Therefore, it became clear that MAK administration increased the amount of exercise in the maze and reduced the level of anxiety. On the other hand, with imipramine administration, a reduction in anxiety level was observed (FIG. 2b), but no increase in momentum in the maze was observed (FIG. 2a).

<試験例2>(強制水泳試験)
強制水泳試験は、被検動物を逃避不可能な水槽内に入れ、それにより引き起こされる絶望状態(無動時間)がヒトでのうつ様症状に類似していること、抗うつ薬の投与により無動時間が短縮し臨床用量とも高い相関性が認められることから、抗うつ薬の特異性の高いスクリーニング法とされている。本試験例では、円柱状の容器に水深25cmの水をはり、その中にラットを入れ、5分間の観察時間のうち動作していない無動時間の割合を求めた。
<Test Example 2> (Forced swimming test)
The forced swimming test is a method in which a test animal is placed in an inaccessible water tank, and the state of despair (immobility time) caused by the test animal is similar to that of depression in humans. It is considered as a screening method with high specificity for antidepressants because it shortens the kinetic time and is highly correlated with the clinical dose. In this test example, water having a depth of 25 cm was poured into a cylindrical container, a rat was put therein, and the proportion of the immobility time during which the operation was not performed was determined within the observation time of 5 minutes.

図3には、基礎検討として、抗うつ薬であるイミプラミンを10mg/kg又は30mg/kgの投与量で、ラットに試験の30分前に腹腔内投与したラット群について強制水泳試験を行ったときの結果を示す。図3に示すように、生理食塩水のみを与えた対照に比べて、イミプラミン投与によりその投与量に依存的に無動時間が低減していることが分かる。   In FIG. 3, as a basic study, when a forced swimming test was performed on a group of rats in which imipramine, an antidepressant, was administered intraperitoneally 30 minutes before the test at a dose of 10 mg / kg or 30 mg / kg. The results are shown. As shown in FIG. 3, it can be seen that immobilization time is reduced depending on the dose of imipramine administration as compared with the control given with physiological saline alone.

図4には、MAK投与群とイミプラミン投与群の投与開始から14日目に行った強制水泳試験の結果を示す。図4に示すように、MAK投与により、水のみを与えた対照に比べて有意に(危険率0.05未満)無動時間が低減していた。また、イミプラミン投与においても有意な無動時間の低減が認められた。   FIG. 4 shows the results of a forced swimming test conducted on the 14th day from the start of administration in the MAK administration group and the imipramine administration group. As shown in FIG. 4, the immobility time was significantly reduced by MAK administration (risk rate <0.05) compared to the control given water alone. A significant reduction in immobility time was also observed with imipramine administration.

(3)培養培地抽出物のその他の調製例
<調製例2>(バガスを用いた椎茸菌の固体培養)
バガス80質量部と、脱脂米糠20質量部とを配合し、水分70%となるように調整して固体培地を作り、常法通り高圧蒸気滅菌した。この固体培地に椎茸の菌糸を接種し、22〜24℃に温度調節した培養室内で4か月間培養し、培地中に菌糸体が蔓延した後、温度処理室に移して32〜34℃で24時間加温し、次いで10℃の低温室で5日間処理した。その後、上記培養室で2日間培養し、培地を破砕機で2回破砕した。破砕した培地を50℃で4時間処理し、自己消化を促進させた後、抽出タンクに詰め、60℃の温水を循環させながら16時間抽出した。得られた抽出液を珪藻土のフィルターケーキで予備濾過し、更にメンブランフィルターで濾過除菌後、濃縮し、凍結乾燥により褐色の粉末を得た。その成分を分析した結果は以下の通りであった。
(3) Other Preparation Examples of Culture Medium Extract <Preparation Example 2> (Solid culture of Shiitake mushroom using bagasse)
80 parts by mass of bagasse and 20 parts by mass of defatted rice bran were blended, adjusted to a moisture content of 70%, a solid medium was prepared, and autoclaved as usual. This solid medium was inoculated with shiitake mycelia and cultured for 4 months in a culture chamber adjusted to a temperature of 22 to 24 ° C. After the mycelium invaded in the medium, it was transferred to a temperature treatment chamber at 24 to 34 ° C. Warm for hours and then treat in a cold room at 10 ° C. for 5 days. Then, it culture | cultivated for 2 days in the said culture room, and the culture medium was crushed twice with the crusher. The crushed medium was treated at 50 ° C. for 4 hours to promote autolysis, then packed in an extraction tank, and extracted for 16 hours while circulating 60 ° C. warm water. The obtained extract was pre-filtered with a filter cake made of diatomaceous earth, further filtered and sterilized with a membrane filter, concentrated, and freeze-dried to obtain a brown powder. The results of analyzing the components were as follows.

・糖質 :35%(フェノール硫酸法)
・蛋白質 :12%(セミミクロケルダール法)
・水溶性リグニン :35%(アセチルブロマイド法)
・無機質 :13%(直接灰化法)
・ Carbohydrate: 35% (phenol sulfate method)
・ Protein: 12% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 35% (acetyl bromide method)
・ Inorganic: 13% (direct ashing method)

<調製例3>(トウモロコシの茎を用いた椎茸菌の固体培養)
トウモロコシの茎を水洗いし乾燥した後、破砕し、米糠を質量比で2割加え、水分70%となるように調整して固体培地を作り、常法通り高圧蒸気滅菌した。この固体培地に椎茸の菌糸を接種し、調製例2と同様にして培養抽出物を得た。その成分を分析した結果は以下の通りであった。
<Preparation Example 3> (Solid culture of Shiitake mushroom using corn stalk)
Corn stalks were washed with water, dried, crushed, and rice bran was added at a mass ratio of 20%, adjusted to 70% moisture, a solid medium was prepared, and autoclaved as usual. Shiitake mycelium was inoculated into this solid medium, and a culture extract was obtained in the same manner as in Preparation Example 2. The results of analyzing the components were as follows.

・糖質 :40%(フェノール硫酸法)
・蛋白質 :12%(セミミクロケルダール法)
・水溶性リグニン :35%(アセチルブロマイド法)
・無機質 :12%(直接灰化法)
・ Sugar: 40% (phenolic sulfuric acid method)
・ Protein: 12% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 35% (acetyl bromide method)
・ Inorganic: 12% (direct ashing method)

<調製例4>(熊笹を用いたマンネン茸菌の固体培養)
熊笹の色素、香りをエチルアルコールで抽出した繊維残渣を破砕したものに米糠を質量比で1割加え、水分70%となるように調整して固体培地を作り、常法通り高圧蒸気滅菌した。この固体培地にマンネン茸の菌糸を接種し、調製例2と同様にして培養抽出物を得た。その成分を分析した結果は以下の通りであった。
<Preparation Example 4> (Solid culture of N. gonorrhoeae using Kumagusu)
10% by mass of rice bran was added to the crushed fiber residue obtained by extracting the pigment and scent of kumabuchi with ethyl alcohol, and a solid medium was prepared by adjusting the water content to 70%, followed by high-pressure steam sterilization as usual. This solid medium was inoculated with mycelium of mannen koji, and a culture extract was obtained in the same manner as in Preparation Example 2. The results of analyzing the components were as follows.

・糖質 :30%(フェノール硫酸法)
・蛋白質 :15%(セミミクロケルダール法)
・水溶性リグニン :35%(アセチルブロマイド法)
・無機質 :10%(直接灰化法)
・ Sugar: 30% (phenolic sulfuric acid method)
・ Protein: 15% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 35% (acetyl bromide method)
・ Inorganic: 10% (direct ashing method)

<調製例5>(バガスを用いた椎茸菌の液体培養)
水1L(リットル)に対し、ミキサーで細かく破砕したバガス60g、乾燥オカラ20g、米糠20g、イーストエキス2gを加え、常法通り高圧蒸気滅菌した。この液体培地に椎茸の菌糸を接種し、23℃で3週間通気培養した後、培養液を60℃で1時間、80℃で2時間加温し、菌糸の酵素による自己消化反応を進行させると共に代謝物を抽出させた。培養液は3,000rpmで30分間遠心分離し、沈殿物を除き、褐色の液を得た。この抽出液を凍結乾燥し、分析した結果は、以下の通りであった。
<Preparation Example 5> (Liquid culture of Shiitake mushroom using bagasse)
To 1 L (liter) of water, 60 g of bagasse finely crushed with a mixer, 20 g of dried okara, 20 g of rice bran, and 2 g of yeast extract were added, followed by high-pressure steam sterilization as usual. This liquid medium is inoculated with mycelia of shiitake mushrooms and aerated for 3 weeks at 23 ° C., and then the culture solution is heated at 60 ° C. for 1 hour and at 80 ° C. for 2 hours to promote the self-digestion reaction of the mycelium enzyme Metabolites were extracted. The culture solution was centrifuged at 3,000 rpm for 30 minutes, the precipitate was removed, and a brown solution was obtained. The extract was lyophilized and analyzed, and the results were as follows.

・糖質 :38%(フェノール硫酸法)
・蛋白質 :16%(セミミクロケルダール法)
・水溶性リグニン :35%(アセチルブロマイド法)
・その他 :11%
・ Carbohydrate: 38% (phenol sulfate method)
・ Protein: 16% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 35% (acetyl bromide method)
・ Other: 11%

<調製例6>(熊笹を用いたマンネン茸菌の液体培養)
熊笹の色素、香りをエチルアルコールで抽出した繊維残渣をミキサーで細かく破砕したものを水1Lに対し90g、米糠10g、イーストエキス5gを加え、常法通り高圧蒸気滅菌した。この液体培地にマンネン茸の菌糸を接種して、23℃で2週間通気培養を行った。培養物は、調製例4と同様の方法で加熱、遠心処理し、濃褐色の液を得た。この抽出液を凍結乾燥し、分析した結果は、以下の通りであった。
<Preparation Example 6> (Liquid culture of gonococcus manneum using bear candy)
90 g, 10 g of rice bran, and 5 g of yeast extract were added to 1 L of water and the fiber residue obtained by extracting the pigment residue and fragrance of Kumagusu with ethyl alcohol finely with a mixer was sterilized under high pressure steam as usual. This liquid medium was inoculated with mycelium of mannen koji, and aerated at 23 ° C. for 2 weeks. The culture was heated and centrifuged in the same manner as in Preparation Example 4 to obtain a dark brown liquid. The extract was lyophilized and analyzed, and the results were as follows.

・糖質 :33%(フェノール硫酸法)
・蛋白質 :18%(セミミクロケルダール法)
・水溶性リグニン :40%(アセチルブロマイド法)
・その他 : 9%
・ Carbohydrate: 33% (phenol sulfate method)
・ Protein: 18% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 40% (acetyl bromide method)
・ Others: 9%

<調製例7>(バガスを用いたヤマブシ茸の固体培養)
バガス65質量部、小麦ふすま20質量部、米糠10質量部、乾燥イースト5質量部を配合し、水分70%となるように調整して固体培地を作り、常法通り高圧蒸気滅菌した。この固体培地にヤマブシ茸の菌糸を接種し、調製例2と同様にして培養抽出物を得た。その成分を分析した結果は以下の通りであった。
<Preparation Example 7> (Solid culture of Yamabushi persimmon using bagasse)
65 parts by mass of bagasse, 20 parts by mass of wheat bran, 10 parts by mass of rice bran, and 5 parts by mass of dry yeast were mixed, adjusted to a moisture of 70%, a solid medium was prepared, and autoclaved as usual. This solid medium was inoculated with mycelium of Yamabushi mushroom, and a culture extract was obtained in the same manner as in Preparation Example 2. The results of analyzing the components were as follows.

・糖質 :43%(フェノール硫酸法)
・蛋白質 :12%(セミミクロケルダール法)
・水溶性リグニン :28%(アセチルブロマイド法)
・無機質 :10%
・ Carbohydrate: 43% (phenol sulfuric acid method)
・ Protein: 12% (semi-micro Kjeldahl method)
・ Water-soluble lignin: 28% (acetyl bromide method)
・ Inorganic: 10%

Claims (2)

バガス及び米糠を含む培地を用いてマンネン茸の菌糸体を培養し、その培養物から抽出して得た、糖質、蛋白質、及び水溶性リグニンを含む抽出物を有効成分として含有することを特徴とする抗うつ剤。 It is characterized by containing, as an active ingredient, an extract containing saccharides, proteins and water-soluble lignin obtained by culturing mycelium of mannen koji using a medium containing bagasse and rice koji and extracting from the culture. An antidepressant. 前記抽出物は、前記培養物から、担子菌の自己消化を行って得られたものである請求項1記載の抗うつ剤。   The antidepressant according to claim 1, wherein the extract is obtained by performing autolysis of basidiomycetes from the culture.
JP2011018027A 2011-01-31 2011-01-31 Antidepressant Active JP5993112B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011018027A JP5993112B2 (en) 2011-01-31 2011-01-31 Antidepressant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011018027A JP5993112B2 (en) 2011-01-31 2011-01-31 Antidepressant

Publications (2)

Publication Number Publication Date
JP2012158536A JP2012158536A (en) 2012-08-23
JP5993112B2 true JP5993112B2 (en) 2016-09-14

Family

ID=46839379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011018027A Active JP5993112B2 (en) 2011-01-31 2011-01-31 Antidepressant

Country Status (1)

Country Link
JP (1) JP5993112B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6082221B2 (en) * 2012-02-13 2017-02-15 日本メナード化粧品株式会社 Differentiation inducer from stem cells to ectoderm cells
CN103110118B (en) * 2013-01-31 2014-06-11 浙江五养堂药业有限公司 Method for preparing dietary fibers by fermenting grifola frondosa residues through hericium erinaceus solids
JP5904378B2 (en) * 2013-02-28 2016-04-13 株式会社エル・エスコーポレーション Antidepressant
CN103405637B (en) * 2013-08-30 2015-07-15 董中影 Drug for treating neurosis and preparation method thereof
CN103549080B (en) * 2013-10-29 2014-09-17 黄毅青 Lung-clearing tea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3284097B2 (en) * 1998-02-19 2002-05-20 野田食菌工業株式会社 Biological antioxidant function enhancer
US6908614B2 (en) * 1999-10-12 2005-06-21 Chee-Keung Chung Anti-aging/menopause symptoms relief using ganoderma lucidum spores
JP2002058450A (en) * 2000-08-17 2002-02-26 (有)日本バイオメディカル研究所 Food product for antidepression
JP2003012538A (en) * 2001-06-28 2003-01-15 Hitoshi Nagaoka Antioxidant agent
JP2005325096A (en) * 2004-04-16 2005-11-24 Taisho Pharmaceut Co Ltd Monoamine reintake inhibitor compounded with grifola frondosa
JP5144112B2 (en) * 2007-04-19 2013-02-13 野田食菌工業株式会社 Brain protectant
JP2009161526A (en) * 2008-12-19 2009-07-23 Tsujido Chemical Corp Treating agent
CN101780120A (en) * 2009-01-19 2010-07-21 包海鹰 Medicinal effect activities of extract of mixture of Poria cum Ligno Hospite and ganoderma and application in medicine

Also Published As

Publication number Publication date
JP2012158536A (en) 2012-08-23

Similar Documents

Publication Publication Date Title
US9394513B2 (en) Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant
CN104982928B (en) A kind of japanese yew fruit health care ferment and preparation method thereof
JP5993112B2 (en) Antidepressant
KR102001740B1 (en) Liquid composition for preventing and relieving hangover with high content of ginsenoside F2, R3 and compound K comprising and preparation method thereof
CN101822373A (en) Golden-fungus gingko functional food, preparation method and use thereof
CN107613997A (en) The extract rich in vitamin D and its composition of edible fungus and their applications in the immune related disorder for the treatment of
JP5144112B2 (en) Brain protectant
JP4602674B2 (en) Maltase inhibitor
JP4783576B2 (en) Antihypertensive
KR20160059137A (en) MANUFACTURE OF FERMENTED Alliumhookeri FROM LACTIC ACID BACTERIA AND NATURAL ENZYME AND PREPARATION OF COMBINED BEVERAGE FOR QUENCHING THIRST
KR20110002621A (en) Manufacturing method of granular tea using phellinus linteus
CN103932180A (en) Pressure-relieving and anti-fatigue health-care food and two-step fermentation preparation method thereof
KR20100126110A (en) Manufacturing method for medicinal wine using turmeic thereof medicinal wine
CN109758485A (en) Purposes of the russule extract in the preparation of preparation treatment and/or prevention intestinal bacilli illness disease and related disease
JP2008208104A (en) Antioxidant, and food and drink
CN106754427B (en) Penicillium lanophorum Kong Junxin strain and domestication method thereof
JP5684989B2 (en) Enzyme-treated and gonococcal fermentation-treated product
CN103932179A (en) Health food for relieving stress and protecting liver and two-step fermentation preparation method of health food
KR101672098B1 (en) Composition for removing hangover comprising fermented rice rinse water
JP5751849B2 (en) Dysphagia improving agent
KR101228554B1 (en) The Fermentation Forming Method of Citrus Sunki And The Product thereof
KR20100037309A (en) Pill type manufacturing method of health supporting food
KR20190014858A (en) A fermented grain and method fot preparing thereof
KR20140084502A (en) For improving liver function with aloe and Curcuma longa and A method of manufacturing the same and Using the formulations for improving liver function
CN110106221B (en) Sea cucumber oligopeptide and preparation method and application thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160819

R150 Certificate of patent or registration of utility model

Ref document number: 5993112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250